IL-SHIPPEO
23.4.2024 10:40:26 CEST | Business Wire | Press release
Shippeo, a leading provider of multimodal shipment visibility, announced today their Spring 2024 Platform release, introducing over 70 new features and enhancements, including a new parcel tracking solution rebuilt from the ground up, as well as improvements to road, ocean container, and carbon emissions tracking, along with significant user experience improvements.
“I’m thrilled to announce that our latest Spring platform release is available to customers from today,” says Chief Product Officer, Anand Medepalli. “Our entirely rebuilt parcel tracking solution that we’re releasing today is market-leading. Reengineered from the ground up, Parcel Visibility offers enhanced scalability to support our continued expansion into North America and APAC, where we are seeing significant appetite for a simpler, more convenient tool that delivers the high data quality and reliability that shippers and freight forwarders demand in this rapidly changing and competitive market. In addition, we’re taking the carbon footprint measurement capabilities for users even further with new Carbon Visibility features, while bringing a number of new features and enhancements to our Road and Ocean Visibility solutions.”
All-new parcel tracking solution to boost customer experience
A newly imagined, simple and convenient parcel tracking solution helps shippers and freight forwarders boost customer experience while accelerating invoicing. With more granular visibility into parcel shipment milestones, recipients have greater oversight of where their shipments are, when they will arrive, while offering shippers easier identification of incomplete delivery root causes. Key features include:
- 360 degree event tracking coverage available after booking, for all major parcel carriers and all in one platform
- Tracking links and customer portals provide recipients with detailed parcel journey information, in client’s own branding
- Aggregated delivery timestamps for users, enabling easy sharing, faster invoicing and optimized cash flow
- On-time In-full performance insights to help users assess carrier performance
Advanced, accurate carbon emissions reporting capabilities enabling targeted reductions
Organizations are increasingly required to measure scope 3 carbon emissions, to comply with rapidly evolving regulations, as a result of stakeholder or customer pressure, or simply to measure progress towards reaching carbon neutrality goals. As a result, carbon emissions reporting continues to rise up the priority list for supply chain management, and shippers in general. Shippeo’s latest Spring Release brings new capabilities to the platform’s GLEC framework-accredited Carbon Visibility solution, making calculations more accurate across all transport modes, and offering powerful insights needed to enable targeted emissions reductions.
- Ocean Carrier Intermodal calculations: Ocean container transport carbon calculations now take into account pre and/or post carriage legs when booked end to end with an ocean carrier, simplifying data collection for a more comprehensive picture of environmental impact, while identifying the most carbon-intensive, and potentially most expensive, legs for door-to-door shipments
- Insetting support: Shippers can now override the default fuel type for truck loads and ocean containers, and select from biofuel and electricity fuel types, to account for lower emissions levels achieved through insetting agreements with road or ocean carriers
- Data completeness dashboards: After launching the same feature for Ocean Visibility users last November, Road Visibility users can now also access a scorecard detailing how complete road shipment data is, identifying missing data, such as weight, truck size, fuel type, and more, to help users take steps to improve calculation accuracy
Further features for Road and Ocean Visibility enhancing user experience, predictive ETA performance, and data quality
The platform update will also introduce new features and enhancements to the Road and Ocean Visibility solutions, including:
- All-new Homepage: An entirely new and fully customizable homepage is coming for all users (including carriers), making it possible to drag and drop widgets and configure their own control center, KPIs and visualize all of their most important action items in one place. Metrics for shipments in various stages can be viewed at a glance, for easier identification and management of deliveries at risk
- Long-distance shipment ETA: Shippeo’s accuracy SLA-backed predictive ETA has been enhanced for full truckload shipments where journey times are two or more days, with accuracy increasing by as much as 70%
- Container Journey identification: Enhanced logic improves identification of container journey boundaries, offering greater data quality when operational processes are more complex and data received from ocean carriers via EDI 315 messages is incomplete
New Developer Portal for more autonomous API integrations and monitoring:
A new portal offers developers a suite of tools for faster, more autonomous API integrations and interface monitoring, for both Shipper and Carrier IT teams, including:
- Full autonomy to interface: Access clear API documentation sorted by transport mode and use-case, examples and screenshots to illustrate steps, explanations of technical language used, and detailed swaggers enabling developers to interface with little to no additional support
- Authentication method selection: Users can choose between JWT or Oauth2 authentication methods
- Integration health monitoring: Self-service analytics, alerts and monitoring allow customers to autonomously check logs and dashboards to monitor the health of their API interfaces and debug errors
About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Arlanxeo, Barilla, Birra Peroni, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, DP World, Evonik, Fujifilm, Jaguar Land Rover, Hartmann Group, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, XPO Logistics and Yamaha Motor, trust Shippeo to track more than 50 million shipments per year across 130 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423236212/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
